Instituto Nacional de Medicina Genómica

The institute carried out research projects aim to improve healthcare through prevention and medical care related to oncogenomics, nutrigenomics and pharmacogenomics.

[6] The current director is Francisco Xavier Soberón, who replaced the founder of the INMEGEN Gerardo Jiménez Sánchez in 2009.

[5] The National Institute of Genomic Medicine's logo represents the sequence of nucleotides of the FOXP2 gene, essential in the development of language.

[2] According to its mission statement, the National Institute of Genomic Medicine contributes to the health care of Mexican society through research projects.

[2] The Institute aims to follow combination of cultural, technological and universal ethics and is concerned in upholding human rights.

It is developing keys for the identification of genes which show a significant increase or decrease in their expression level of fibrosis in preneoplastic and neoplastic lesions in the liver.

Other project is the decodification of the AH1N1 flu virus, with research into the genetic susceptibility of the Mexican population to acquire this illness.

Proteomics studies involve the analysis of protein additions of lipid peroxidation at liver carcinogenesis.

[8] One of the Institutions pharmacogenomics investigations is working with the doses guided by genotype-phenotype and in their standard management in patients who initiate anticoagulation with acenocoumarol.

This study is carried out in individuals genetically isolated of the La Huasteca area of San Luis Potosí.

Another study is on the effect of Omega 3 on metabolic syndrome in the Mexican population, specifically on early biomarkers presented in the diabetic nephropathy and the risk factors for developing obesity.

In autoinmune genomics, INMEGEN investigates the risk factors for juvenile idiopathic arthritis in the Mexican population.

In the case of bone metabolism genomics, the institution focuses on studying mineral density and osteoporosis in Mexican women.

[9] In 2008 INMEGEN and the Mexico City government signed an agreement for the elaboration of the complete genome map of the mestizo population of the country's capital.

[10] INMEGEN, like other research institutions, experiences “brain drain”, which is Mexican talented scientists leaving the country because of the lack of opportunities.